Times of India (06.14.2013)
For the first time in 40 years, the World Health Organization (WHO) has issued interim guidance for the use of a new TB drug, bedaquiline, in the combination therapy for multi-drug resistant TB. The US Food and Drug Administration approved the drug last year. WHO’s interim guidance listed five conditions that must be in place if the new drug is to be used. Those conditions included close monitoring for effectiveness and safety, proper patient inclusion, informed consent, adherence to WHO recommendations, ensuring early detection and management of adverse drug reactions and potential interactions with other drugs.